Methylphenidate-class side effects (same as Ritalin/Concerta)

• Common (>10%): Decreased appetite, insomnia, headache, nausea, weight loss, irritability.
• Less common (1-10%): Increased BP/HR, dry mouth, anxiety, mood swings, bruxism, tics, dizziness.
• Rare-serious (<1%): Cardiovascular events (FDA boxed warning), psychiatric reactions (psychosis, mania), priapism, peripheral vasculopathy/Raynaud's, serotonin syndrome (with serotonergic combinations).

Daytrana-specific (transdermal-route)

• Application-site reactions (>30%): Erythema, itching, contact dermatitis, edema. Often manageable with site rotation and emollients between applications, but can be persistent.
• Chemical leukoderma / permanent skin depigmentation (RARE-SERIOUS): Per the FDA Drug Safety Communication June 24, 2015, Daytrana labeling was updated to warn that the patch can cause chemical leukoderma — a permanent loss of skin color at and around the application site. Reports describe patches of pale or white skin that can be several centimeters in diameter and have been described as affecting hands, feet, and other areas distant from the application site (vitiligo-like). This is a cosmetic injury that does not reverse with discontinuation. The condition does not affect overall health but is irreversible. Per the FDA action, healthcare providers must advise patients of this risk; patients/parents must inspect application sites at each rotation and discontinue at first sign of skin discoloration. While this is technically a label warning rather than a black box per se, it is one of the more clinically meaningful rare-serious adverse effects in stimulant pharmacology and is specific to Daytrana (not seen with oral methylphenidate).
• Heat-induced dose dumping: Heat increases transdermal flux. Hot tubs, saunas, heating pads, fever, prolonged sun exposure, and strenuous exercise can all elevate plasma methylphenidate beyond intended levels, with associated cardiovascular and psychiatric risk. The FDA label specifically advises against heat exposure during patch wear.
• Adhesive failure: Sweat, water exposure, friction (clothing, contact sports, grappling), and oily skin all reduce adhesion. A partially detached patch delivers an unknown fraction of intended dose.

Specific watch periods

• Application-site skin watch: Inspect each rotation site at every patch change and weekly photograph baseline if continuing Daytrana long-term. First sign of pale/white patches → discontinue and refer to dermatology.
• First 2-4 weeks: BP/HR titration, psychiatric emergence, sleep impact.
• Long-term: Annual cardiovascular check, growth monitoring (children), application-site dermatologic check.